Each year, millions of people make goals to lose weight and get healthier. There are tons of products and supplements on the market that claim to assist in helping people lose weight. Lorcaserin, also known as Belviq, is one of them.

Belviq is a weight-loss drug developed by Arena Pharmaceuticals and later sold to Eisai Inc. As of June 2012, Belviq is FDA approved as a prescription pill for people living with obesity.  It is not available over the counter; it must be prescribed by a medical doctor. Belviq works by activating a serotonin receptor in the hypothalamus, which is an area of the brain that controls appetite.

Belviq is available as both a tablet, and an extended-release tablet (Belviq XR). Its expected results are only a 5% weight loss. If you are interested in learning about The Ruth Law Team and Belviq cases, please call us at 888-783-8378.

What have Belviq studies shown?

In 2007, studies showed that lorcaserin caused cancer in studies on rats. In fact, over the two-year study, results consistently showed metastatic cancer in the animals. Allegations suggest Arena modified the study results to show the tumors were benign rather than malignant. Additionally, they claimed the animal study results were not relevant to humans. Ultimately, Arena Pharmaceuticals hired a toxicologist, who stated that Lorcaserin does not pose a cancer risk to humans at the recommended therapeutic dose.

In 2010, the FDA rejected market approval by a 9-4 vote, recognizing the drug clearly caused tumors in animals. A Pathology Working Group (PWG) convened and submitted a new report to the FDA, finding in favor of the safety of the drug. It said the drug did not pose a problem for humans and there was not a cancer risk for humans. In May 2012, the FDA then approved the drug for market in an 18-4 vote. At that time, however, the FDA required Eisai to conduct a study evaluating the potential cardiovascular risks of the weight-loss drug.

Is Belviq still on the market?

In January of 2020, the FDA alerted the public that there is a possible increased risk of cancer associated with Belviq. On February 13, 2020, the Food and Drug Administration (FDA) announced that Eisai Inc. agreed to voluntarily withdraw both Belviq and Belviq XR from the market.

What type of cancer does Belviq cause?

Belviq may be associated with an increased risk of the following types of cancer:

  • Colorectal cancer
  • Lung cancer
  • Pancreatic cancer
  • Brain cancer
  • Thyroid cancer
  • Breast cancer

Do I have a Belviq Case?

You may have a Belviq case if you used Belviq and were later diagnosed with cancer. Our consultations are completely free and confidential. The Ruth Law Team has been handling personal injury and product liability cases for more than 35 years.  Our team is dedicated to the fight for justice. We fight insurance companies and large corporations daily on behalf of our clients. For more information on our Belviq case investigations, call us at 888-783-8378 or simply fill out the free consultation request form on this page. A member of our legal team will be in touch with you shortly.